Clinical Efficacy and Impact on Cardiac Function of Levosimendan in Elderly Patients with Acute Exacerbation of Chronic Heart Failure

YANG Fan; LEI Ming

doi:10.13919/j.issn.2095-6274.ZHJY202412045

Abstract：Objective This study aims to investigate the clinical efficacy of levosimendan in treating elderly patients with acute exacerbation of chronic heart failure and its impact on cardiac function.Methods A total of 100 elderly patients with acute exacerbation of chronic heart failure who were treated at the Shandong Provincial Public Health Clinical Center from March 2021 to March 2024 were selected.Using a random number table meth-od,patients were divided into two groups:the study group and the control group,with 50 patients in each group.The control group received standard heart failure treatment along with recombinant human brain natriuretic peptide therapy,while the study group received levosimendan in addition to the treatment provided to the control group.Clinical efficacy,cardiac function indicators,serological markers,walking distance,and adverse re-actions were compared between the two groups.Re-sults The overall clinical efficacy rate in the study group was significantly higher than that in the control group(P＜0.05).After treatment,both groups exhibited significant increases in left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac index(CI),and stroke volume(SV)compared to baseline values(P＜0.001).The study group demonstrated higher levels of LVEF,SV,and CI than the control group(P＜0.001).Additionally,both groups showed a significant reduction in LVEDD after treatment(P＜0.001),with the study group having a lower LVEDD compared to the con-trol group(P＜0.001).Post-treatment serological markers,including amino-terminal pro-B-type natriuretic peptide(NT-proBNP),interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),and cardiac troponin Ⅰ(cTnⅠ),were significantly lower than baseline levels in both groups(P＜0.001),with the study group exhibiting reduced lev-els of NT-proBNP,cTnⅠ,hs-CRP,and IL-6 compared to the control group(P＜0.001).The 6-minute walk test(6MWT)distance significantly increased in both groups post-treatment(P＜0.001),with a more pronounced improvement ob-served in the study group(P＜0.001).The overall incidence of adverse reactions did not differ significantly between the two groups(P＞0.05).Conclusion In elderly patients with acute exacerbation of chronic heart failure,ad-junctive treatment with levosimendan can enhance clinical efficacy,improve cardiac function,and protect myocar-dial cells,demonstrating a high safety profile.